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Purpose: We report herein 119 patients with pheochromocytoma at our institute 
over the last 23 years. Materials and Methods: Between 1986 and 2009, 119 pa-
tients were diagnosed with pheochromocytoma at our institute. We reviewed the 
medical records of these patients. Results: Of 119 patients, 45 were male and 74 
were female, and mean age was 43.83 ± 13.49 years. Forty-three patients (36.1%) 
were diagnosed incidentally, and 8 patients (6.7%) were found to have familial 
pheochromocytoma. The mean dimension of the tumors was 5.89 ± 3.18 cm. 4 pa-
tients had bilateral tumors; three of these patients were found to have familial 
pheochromocytoma and 1 patient was diagnosed with malignant pheochromocy-
toma. A total of eight patients (6.7%) were found to have malignant pheochromo-
cytoma. In 1 patient, metastasis to a lymph node was found at the time of diagno-
sis. Metastases were found at a mean of 49 ± 25.83 (6-75) months after surgery in 
the other seven patients. 6 patients died of malignant pheochromocytoma at a 
mean of 31 ± 28.71 months (1-81) after diagnosis, and the other 2 patients sur-
vived for 15 and 24 months, respectively. Conclusion: Approximately 35% of pa-
tients with pheochromocytoma are diagnosed incidentally, and the number of de-
tected cases is increasing. Although familial pheochromocytoma was found only 
in 6.7% of the patients, genetic testing should be considered in all patients, espe-
cially in patients with a family history, young age, or multifocal, bilateral, extra-
adrenal, or malignant tumors. Given that malignant pheochromocytomas are fre-
quently diagnosed during the follow-up period, long-term follow-up is necessary 
to confirm the absence of recurrence or metastasis.
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INTRODUCTION
Pheochromocytomas are tumors that arise from chromaffin tissue. While most 
pheochromocytomas arise usually in the adrenal medulla, there are also extra-ad-
renal pheochromocytomas (paragangliomas) that arise in an extra-adrenal site 
along the sympathetic or parasympathetic chain.1 Pheochromocytomas produce 
and secrete catecholamines that cause a variety of clinical symptoms, including 
headache, sweating, paroxysmal or sustained hypertension, and heart palpitations. 
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guanadine (131I-MIBG) scintigraphy was performed, the re-
sults were compared with the pathologic findings.
The diagnosis of malignancy was based on the presence of 
metastasis. In patients who were diagnosed with malignant 
pheochromocytoma, the time of diagnosis and the treatment 
of the malignancy were reviewed. If the patient was de-
ceased, the time from diagnosis to death was also noted.
RESULTS
Of 119 patients, 45 were male and 74 were female, and mean 
age at surgery was 43.83 ± 13.49 (11-74) years (Table 1). 
Symptoms associated with pheochromocytoma were docu-
mented in 99 patients (83.2%). However, 43 patients 
(36.1%) were diagnosed with pheochromocytoma inciden-
tally during a routine medical exam or during imaging stud-
ies for unrelated disorders, regardless of the presence of 
symptoms. Of 43 patients, ten cases occurred prior to 2000. 
Persistent hypertension was present in 49 patients (41.1%), 
and diabetes was present in 26 patients (21.8%). Sporadic 
cases of pheochromocytoma accounted for 111 patients 
(93.3%), while eight patients (6.7%) were associated with 
familial syndromes. Of these eight cases, six were multiple 
endocrine neoplasia type 2 (MEN2), one case was neurofi-
bromatosis (NF), and one case was von Hippel-Lindau 
(VHL) syndrome. The mean age of the patients with familial 
These symptoms can result in a decreased quality of life.
Pheochromocytomas are relatively rare tumors found in 
approximately 4% of adrenal incidentalomas.2 However, 
the number of tertiary center referrals for pheochromocyto-
mas are reportedly increasing, likely as a result of improved 
detection.3 Due to the rarity of this disease, there have not 
been many large-scale studies regarding its clinical charac-
teristics. Goldstein, et al.4 reported 104 patients with pheo-
chromocytoma over a period of 48 years, and Mannelli, et 
al.5 reported a multicentric study of 284 patients with pheo-
chromocytoma. In Korea, Lee and Oh6 reported clinical 
evaluation of pheochromocytoma in only 12 patients in 
1993. Other studies regarding pheochromocytoma are pri-
marily case reports. 
We investigated the medical records of 119 patients with 
pheochromocytoma at our institute over the last 23 years 
and analyzed their epidemiological, clinical, laboratory, ra-
diological, and pathological data. 
MATERIALS AND METHODS
From 1986 to 2009, 119 patients were diagnosed with pheo-
chromocytoma at our institute, and all were included in our 
study. All patients underwent surgical excision of their tumor, 
and the diagnosis was confirmed by pathological findings in 
all cases. Records of epidemiological, clinical, laboratory, ra-
diological, and pathological data were retrospectively re-
viewed and analyzed.
We investigated the presence of associated symptoms in-
cluding anxiety, visual blurring, palpitations, headache, 
sweating, and abdominal pain. We also investigated wheth-
er patients presented with associated symptoms or if an ad-
renal mass was incidentally found during a routine medical 
exam or imaging study. We also investigated the presence of 
persistent hypertension or diabetes and any possible associ-
ation with familial pheochromocytoma syndromes. 
Laboratory studies included 24-hour measurements of to-
tal urinary catecholamines, epinephrine, metanephrine, nor-
epinephrine, dopamine, vanillylmandelic acid, and plasma 
metanephrine, norepinephrine, and epinephrine. Laboratory 
studies were considered abnormal in cases where these val-
ues were elevated.
Tumor location and dimensions were obtained from ra-
diologic studies, including computed tomography (CT), 
magnetic resonance imaging, and positron emission tomog-
raphy. In cases where iodine-131-labeled metaiodobenzyl-
Table 1. Features of the Patients and Their Tumors
Total (%)
Gender
    Male 45 (37.8)
    Female 74 (62.2)
Age (yrs)
    Range 11 - 74
    Mean ± SD 43.83 ± 13.49
Hypertension 49 (41.1)
Diabetes   26 (21 / 8)
Familial pheochromocytoma 8 (6.7)
    NEN2 6
    NF 1
    VHL syndrome 1
Tumor size (cm)
    Range 1.0 - 15.0
    Mean ± SD 5.89 ± 3.18
Laterality (Rt / Lt / Bil) 68 / 47 / 4 (57.1 / 39.5 / 3.4)
MEN2, multiple endocrine neoplasia type 2; NF, neurofibromatosis; VHL, 
von Hippel-Lindau.
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patients was 49.63 ± 11.94 (28-71) years. In 1 patient, a 
metastatic lymph node in the neck was found at the time of 
diagnosis of pheochromocytoma. The patient underwent 
surgical excision of the tumor and radiotherapy for bone 
metastasis; the patient subsequently died of malignant 
pheochromocytoma 27 months after diagnosis. 7 patients 
were diagnosed with malignant pheochromocytoma at a 
mean of 49 ± 25.83 (6-75) months after surgery because of 
metastases to the liver, lung, bone, or lymph nodes. Of 
these seven patients, five died of malignant pheochromocy-
toma. The mean time to death for the 6 patients who died of 
malignant pheochromocytoma was 31 ± 28.71 (1-81) 
months. 2 patients received a regimen of cyclophosphamide, 
vincristine, and dacarbazine (CVD) chemotherapy; one of 
these patients received radiotherapy also for bone metastasis. 
Of the three patients who received conservative care, one 
died one month after treatment, one died seven months after 
treatment, and one patient died at 81 months after treat-
ment. Two patients survived for 15 and 24 months, respec-
tively, into the follow-up period. One patient underwent 
131I-MIBG treatment for lung metastasis, and the other pa-
tient underwent surgical excision of lung and lymph node 
metastases.
DISCUSSION
In the present study, we reviewed the records of 119 pa-
tients with pheochromocytoma and confirmed variable 
clinical features of the disease. Hypertension, whether sus-
tained or paroxysmal, is the most common clinical sign, 
and headache, excessive truncal sweating, and palpitations 
are the most common symptoms.7 In a retrospective study 
of 41 patients with pheochromocytoma, blood pressure 
syndromes was 39.88 ± 14.37 (25-71) years. 
Fifteen patients showed normal laboratory values. Ten of 
these patients underwent preoperative management for sus-
pected pheochromocytoma, while the other five underwent 
surgery without preoperative management. Three of these 
patients exhibited severe changes in blood pressure during 
surgery. The most commonly used medication for preoper-
ative treatment was phenoxybenzamine, which was utilized 
in 90 patients (75.6%). Doxazosin was used in 21 patients 
(17.6%), and prazosin was used in three patients (2.5%). In 
6 patients (5%), beta-blockers were administered in addi-
tion to an alpha-blocker. The length of preoperative man-
agement was variable with a range of two to eight weeks.
The mean dimension of the tumors, according to radiolog-
ic studies, was 5.89 ± 3.18 (1.0-15.0) cm. Forty-seven tumors 
(39.5%) were left-sided, 68 (57.1%) were right-sided, and 
four (3.4%) were bilateral. Of the 4 patients with bilateral tu-
mors, two were associated with MEN2, and one was associ-
ated with VHL syndrome. The other patient was diagnosed 
with malignant pheochromocytoma. 25 patients received 131I-
MIBG scintigraphy. The study yielded false negative results 
in 6 patients, with two of these patients being asymptomatic 
and showing normal values in laboratory studies. 
Of our 119 cases of pheochromocytoma, 43 patients 
(36.1%) underwent laparoscopic surgery. Laparoscopic sur-
gery was first performed at our institute in 1990, and the 
first laparoscopic adrenalectomy was performed in 1996. 
Forty of the 43 cases of laparoscopic adrenalectomy were 
performed after 2000. 
8 patients were diagnosed with malignant pheochromo-
cytoma, which was established in the presence of distant 
metastasis either at the time of diagnosis or during follow-
up (Table 2). The mean dimension of the malignant tumors 
was 7.81 ± 4.01 (3.0-15.0) cm, and the mean age of these 
Table 2. Features of Eight Patients with Malignant Pheochromocytoma
No. Gender Age
Tumor size 
(cm)
Laterality
Time from 
surgery to 
diagnosis (months)
Metastatic 
organs
Treatment
Survival /
death
Time to sur-
vival /death
1 F 43 3 Right   6 Liver, LN Conservative Tx Death   1
2 F 52 11 Left 20 Bone, liver CTx + RTx Death 28
3 F 51 4 Right 60 LN Conservative Tx Death 81
4 M 50 15 Left 58 Liver, lung Conservative Tx Death   7
5 F 54 8 Bilateral   0 Bone, LN RTx Death 27
6 M 71 6 Left 69 Lung CTx Death 42
7 F 28 10 Left 55 Lung, LN Metastatectomy Survival 24
8 F 48 5.5 Right 75 lung 131I-MIBG Survival 15
LN, lymph nodes; Tx, treatment; CTx, chemotherapy; RTx, radiotherapy; 131I-MIBG, iodine-131-labeled metaiodobenzylguanadine.  
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ated strongly with extra-adrenal and malignant pheochro-
mocytoma.18-20 Whether or not genetic testing should be 
performed in all patients with sporadic pheochromocytoma 
remains controversial. In a previous study, approximately 
one-fourth of patients with pheochromocytoma were found 
to have mutations, and some authors have suggested that 
genetic testing should be offered to all patients.21,22 Howev-
er, Pigny, et al.22 suggested that genetic testing should be 
performed in patients who were diagnosed before age 20 
(prevalence of hereditary forms: 33.3%) or who had a bilat-
eral pheochromocytoma (prevalence: 75%) and should be 
strongly recommended in patients diagnosed prior to age 
50 (cumulative prevalence: 10.4%). They did not recom-
mend genetic testing in patients with a unilateral pheochro-
mocytoma diagnosed after 50 years of age. In our study, 
only eight patients (6.7%) were associated with familial 
syndromes. Four of these patients were found to have 
MEN2 and were diagnosed with pheochromocytoma only 
after surgery for medullary thyroid cancer; genetic testing 
was not performed in the majority of these patients. 
The diagnosis of pheochromocytoma is usually based on 
biochemical testing in suspected patients or in patients with 
an incidentaloma. Biochemical evidence of excessive cate-
cholamine production is an essential step in the diagnosis of 
pheochromocytoma. However, many physiologic stimuli, 
drugs, and clinical conditions can produce false-positive re-
sults. Furthermore, pheochromocytomas do not always se-
crete enough catecholamines to produce positive test results 
and often secrete catecholamines only episodically.7 Miss-
ing the diagnosis of pheochromocytoma can lead to cata-
strophic consequences. In this study, fifteen patients (13%) 
demonstrated normal values in laboratory testing. Five of 
these patients did not have clinical symptoms or signs sug-
gestive of pheochromocytoma, and therefore, preoperative 
management was not performed. Three patients demon-
strated severe changes in blood pressure during surgery. In 
order to establish an accurate diagnosis, it is advisable to 
perform two independent urinary collections to account for 
the episodic nature of pheochromocytoma.1 Unfortunately, 
laboratory studies were not performed twice in the 15 pa-
tients who had false-negative results. Measurement of the 
plasma levels of metanephrine is more sensitive than those 
of other biochemical tests.1,7 The sensitivity of plasma 
metanephrine level is nearly 99%, and the specificity has 
been reported to range from 85% to 89%.23,24 Furthermore, 
a plasma metanephrine measurement is also sufficient to 
exclude pheochromocytoma because of its high negative-
anomalies led to the discovery of pheochromocytoma in 
only 51% of patients, and only 59% of patients suffered 
from hypertension. In our review, 47 patients (41.1%) were 
found to have suffered from persistent hypertension, and 99 
patients (83.2%) presented with symptoms associated with 
pheochromocytoma. Pheochromocytoma was found inci-
dentally in 43 patients (36.1%), only ten of whom were di-
agnosed prior to 2000. Kopetschke, et al.8 reported that ap-
proximately 30% of pheochromocytomas are detected 
incidentally, and that this proportion is increasing. This in-
crease in detection is likely due to increasing availability of 
imaging procedures. 
Diabetes is also frequently found in patients with pheo-
chromocytoma and is related to catecholamine-induced in-
sulin resistance and insulin suppression.9 The reported inci-
dence of diabetes in patients with pheochromocytoma varies 
from 15.5% to 48.3%.10-13 In young patients with hyperten-
sion and a normal body weight, the presence of diabetes is 
a clinical predictor of pheochromocytoma.9 However, the 
symptoms and signs of pheochromocytoma are variable 
and non-specific, therefore, clinical detection of pheochro-
mocytoma is very difficult, and diagnosis is sometimes de-
layed or missed completely.5,14 This may explain relatively 
high prevalence of pheochromocytoma discovered at au-
topsy, approximately 0.05%.15,16
It is widely believed that approximately 10% of pheo-
chromocytomas are associated with familial syndromes, 
however, it is now recognized that the frequency of germ-
line mutations in apparently sporadic presentations is as 
high as 15% to 24%.1 Sporadic pheochromocytoma is usu-
ally diagnosed in individuals between 40 and 50 years of 
age, whereas hereditary forms are diagnosed earlier, most 
often before the age of 40.14 The probability of developing 
bilateral or multifocal tumors is higher in hereditary forms.17 
In the present study, 75% (3/4) of bilateral tumors were as-
sociated with familial pheochromocytoma syndromes, and 
a CT image of a patient with VHL syndrome showed multi-
ple and bilateral tumors. Germline mutations in six genes 
are related to familial pheochromocytoma. Prior to 2000, it 
was thought that familial pheochromocytoma was caused 
by germline-inactivating mutations in the RET proto-onco-
gene for MEN2, mutations in the tumor suppressor gene 
VHL, and mutations in the NF1 genes. More recently, the 
succinate dehydrogenase D, B, and C (SDHD, SDHB, 
SDHC) genes, which are associated with familial pheo-
chromocytoma and/or paraganglioma syndrome, have been 
identifed.14 Of these six genes, SDHB mutations are associ-
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predictive value.25 Thus, many authors recommend to ob-
tain a plasma metanephrine measurement as an initial bio-
chemical test.1,7,23
The World Health Organization’s definition of a malig-
nant pheochromocytoma is the presence of metastasis; the 
diagnosis of malignancy can be made only retrospectively 
when metastases have become evident. Metastases occur 
most frequently in the bone, liver, lungs, and lymph nodes, 
and can appear as many as 20 years after initial presenta-
tion.1 Clinical, biochemical, and radiological features are 
inadequate to either predict malignancy or to distinguish 
benign from malignant lesions. Local invasion and various 
histopathological features can be suggestive of malignancy, 
however, these features are not widely accepted, and more 
sensitive and specific diagnostic means need to be devel-
oped.17 In general, tumors that are large (> 5 cm) or have an 
extra-adrenal location have a higher risk for malignant dis-
ease, and paraganglioma in patients with SDHB gene muta-
tions have a particularly high rate of malignant disease.14 
The overall five-year survival in patients with malignant 
pheochromocytoma ranges from 40% to 74%.17 At present, 
there is no effective treatment for malignant pheochromo-
cytoma. Treatment with 131I-MIBG or combination chemo-
therapy (cyclophosphamide, vincristine, and dacarbazine) 
has produced disappointing results, producing only short-
lived remissions.14 Recently, attempts have been made to 
create targeted therapies interfering with specific pathways 
within pheochromocytoma cells. Park, et al.26 reported a 
case of malignant pheochromocytoma that demonstrated a 
good metabolic response to sunitinib. 
Tumor recurrence has been reported in up to 17% of pa-
tients in a large study.27 There are no reliable tests available to 
distinguish benign from malignant pheochromocytomas. 
Thus, all patients should be followed-up indefinitely, and 
long-term clinical and biochemical assessments are neces-
sary. In this study, the proportion of patients with familial 
pheochromocytoma might have been underestimated be-
cause genetic testing was not performed in most patients. 
However, genetic testing should be considered in all patients, 
especially in patients with a family history, young age, and/or 
multifocal, bilateral, extra-adrenal, or malignant tumors.
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